JP2003511466A - 修飾ｐｎａ分子 - Google Patents

修飾ｐｎａ分子

Info

Publication number
JP2003511466A
JP2003511466A JP2001530466A JP2001530466A JP2003511466A JP 2003511466 A JP2003511466 A JP 2003511466A JP 2001530466 A JP2001530466 A JP 2001530466A JP 2001530466 A JP2001530466 A JP 2001530466A JP 2003511466 A JP2003511466 A JP 2003511466A
Authority
JP
Japan
Prior art keywords
pna
peptide
modified
amino acid
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001530466A
Other languages
English (en)
Japanese (ja)
Inventor
ニールセン，ペーテル・イー
グッド，リーアム
ハンセン，ヘンリク・フリーデンルンド
ベック，フレデリク
マリク，レイラ
ショウ，カルステン
ウィッセンバッハ，マルギット
ギウェルクマン，ビルギット・キェルドガルド
Original Assignee
パンセコ・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK199801467A external-priority patent/DK173006B1/da
Application filed by パンセコ・アクティーゼルスカブ filed Critical パンセコ・アクティーゼルスカブ
Publication of JP2003511466A publication Critical patent/JP2003511466A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
JP2001530466A 1998-11-11 2000-10-13 修飾ｐｎａ分子 Pending JP2003511466A (ja)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
DK199801467A DK173006B1 (da) 1998-11-11 1998-11-11 Fremgangsmåde og anlæg til frembringelse af vægmateriale til brug ved fremstilling af kompensatorer, navnlig til røggaskanaler, samt kompensatormateriale og kompensator frembragt ved fremgangsmåden
DK199901471 1999-10-13
DK199901467 1999-10-13
DKPA199901471 1999-10-13
US15968499P 1999-10-15 1999-10-15
US15967999P 1999-10-15 1999-10-15
US60/159,679 1999-10-15
US60/159,684 1999-10-15
DK199901734 1999-12-03
DK199901735 1999-12-03
DKPA199901735 1999-12-03
DKPA199901734 1999-12-03
DK200000522 2000-03-28
DKPA200000522 2000-03-28
DK200000670 2000-04-19
DKPA200000670 2000-04-19
DKPA200000671 2000-04-19
DK200000671 2000-04-19
US21187800P 2000-06-14 2000-06-14
US21175800P 2000-06-14 2000-06-14
US21143500P 2000-06-14 2000-06-14
US60/211,435 2000-06-14
US60/211,758 2000-06-14
US60/211,878 2000-06-14
PCT/DK2000/000580 WO2001027261A2 (en) 1998-11-11 2000-10-13 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino

Publications (1)

Publication Number Publication Date
JP2003511466A true JP2003511466A (ja) 2003-03-25

Family

ID=27582959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001530466A Pending JP2003511466A (ja) 1998-11-11 2000-10-13 修飾ｐｎａ分子

Country Status (8)

Country Link
EP (1) EP1220902A2 (de)
JP (1) JP2003511466A (de)
AU (1) AU7773000A (de)
CA (1) CA2388991A1 (de)
HU (1) HUP0203465A2 (de)
IL (1) IL149095A0 (de)
NO (1) NO20021711L (de)
WO (1) WO2001027261A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072743A1 (en) * 2000-04-06 2004-04-15 Christensen Jeppe Viggo Pharmaceutical composition of modified pna molecules
WO2002015896A2 (en) * 2000-08-25 2002-02-28 Trustees Of Tufts College Methods and compositions for potentiating antibiotic action against persistent/tolerant pathogenic microorganisms
WO2002042316A2 (en) * 2000-11-24 2002-05-30 Pantheco A/S Pna analogues
WO2002053574A2 (en) * 2001-01-05 2002-07-11 Pantheco A/S Modified pna molecules
WO2002079467A2 (en) * 2001-03-29 2002-10-10 Københavns Universitet Antibiotic-free bacterial strain selection with antisense molecules
WO2003092736A2 (en) * 2002-05-01 2003-11-13 Pantheco A/S Peptide nucleic acid conjugates with transporter peptides
US20090030257A1 (en) * 2007-07-25 2009-01-29 Ceramoptec Industries Inc. Anti-microbial photodynamic therapy
ES2641290T3 (es) 2007-11-20 2017-11-08 Ionis Pharmaceuticals, Inc Modulación de la expresión de CD40
EP3204402B1 (de) * 2014-10-09 2022-02-16 ENDO Biologics, Inc. Selbstanordnende tripeptide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082830A (en) * 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
US6451968B1 (en) * 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
DE69527857T2 (de) * 1994-10-06 2003-05-28 Buchardt, Dorte Peptid-nukleinsäure-konjugate
US5834430A (en) * 1995-05-31 1998-11-10 Biosynth S.R.L. Potentiation of antibiotics
WO1998032467A2 (en) * 1997-01-24 1998-07-30 Antivirals, Inc. Method and conjugate for treating h. pylori infection
EP0975370B9 (de) * 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen
US6025140A (en) * 1997-07-24 2000-02-15 Perseptive Biosystems, Inc. Membrane-permeable constructs for transport across a lipid membrane
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
DE04020014T1 (de) * 1997-09-12 2006-01-26 Exiqon A/S Bi-zyklische - Nukleosid,Nnukleotid und Oligonukleotid-Analoga
US6300318B1 (en) * 1997-09-16 2001-10-09 Peter E. Nielsen Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor

Also Published As

Publication number Publication date
EP1220902A2 (de) 2002-07-10
WO2001027261A2 (en) 2001-04-19
HUP0203465A2 (hu) 2003-01-28
AU7773000A (en) 2001-04-23
NO20021711D0 (no) 2002-04-11
NO20021711L (no) 2002-06-11
WO2001027261A3 (en) 2002-02-28
CA2388991A1 (en) 2001-04-19
IL149095A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
US6548651B1 (en) Modified peptide nucleic acid (PNA) molecules
US6300318B1 (en) Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
US7169756B2 (en) Streptogramin antibiotics
EP3569252B1 (de) Antibakterielle antisense-verbindungen und verfahren
Castillo et al. Antimicrobial synergy between mRNA targeted peptide nucleic acid and antibiotics in E. coli
US20040072743A1 (en) Pharmaceutical composition of modified pna molecules
JP7393121B2 (ja) アンチセンス抗菌化合物および方法
WO2006127715A1 (en) Antimicrobial peptides
JP2003511466A (ja) 修飾ｐｎａ分子
WO2003092736A2 (en) Peptide nucleic acid conjugates with transporter peptides
JP6600621B2 (ja) 黄色ブドウ球菌感染の治療のためのアンチセンス分子
US20160177297A1 (en) Antisense molecules for treatment of staphylococcus aureus infection
JP4524671B2 (ja) 抗菌ペプチド及びその利用
WO2002053574A2 (en) Modified pna molecules
JP2004514427A (ja) Ｐｎａ類似物
JP2003511068A (ja) Ｐｎａを使用した遺伝子選択
ZA200202455B (en) Conjugates between a peptides and a nucleic acid analog, such as PNA, LNA or a morpholino.
WO2003092735A2 (en) Peptide nucleic acid conjugates with beta-amino acid polymers or reptoids
JP2001510164A (ja) 動物に対する毒性を減じた生物活性ペプチドおよび同ペプチドを調製する方法。
JP2005532784A (ja) 新規の抗菌ボリシンペプチド